Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
PetVivo Holdings Inc (PETV)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: PETV (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7
1 Year Target Price $7
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -54.64% | Avg. Invested days 22 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 25.11M USD | Price to earnings Ratio - | 1Y Target Price 7 |
Price to earnings Ratio - | 1Y Target Price 7 | ||
Volume (30-day avg) 1 | Beta 0.76 | 52 Weeks Range 0.40 - 0.98 | Updated Date 09/15/2025 |
52 Weeks Range 0.40 - 0.98 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.39 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -619.94% |
Management Effectiveness
Return on Assets (TTM) -100.41% | Return on Equity (TTM) -379.92% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 23235974 | Price to Sales(TTM) 19.22 |
Enterprise Value 23235974 | Price to Sales(TTM) 19.22 | ||
Enterprise Value to Revenue 17.79 | Enterprise Value to EBITDA -8.68 | Shares Outstanding 27903400 | Shares Floating 21570414 |
Shares Outstanding 27903400 | Shares Floating 21570414 | ||
Percent Insiders 41.1 | Percent Institutions - |
Upturn AI SWOT
PetVivo Holdings Inc
Company Overview
History and Background
PetVivo Holdings, Inc. was founded in 2010. It focuses on developing and commercializing innovative medical devices and therapeutics for pets, particularly those with osteoarthritis and other joint-related conditions. The company's core technology involves biocompatible hydrogels for joint lubrication and regeneration.
Core Business Areas
- Medical Devices: Development and commercialization of injectable medical devices for the treatment of osteoarthritis and other joint conditions in animals.
- Therapeutics: Research and development of therapeutic products aimed at improving the quality of life for animals.
Leadership and Structure
The company is led by a management team with experience in animal health and medical device development. Executive leadership includes a CEO, CFO, and heads of research and development, and sales & marketing.
Top Products and Market Share
Key Offerings
- Spryng with OsteoCushion Technology: An injectable medical device intended to treat osteoarthritis in dogs and horses by lubricating the joint. Market share data is not publicly available. The competitors would be other veterinary medicine and treatment options for osteoarthritis such as surgery or pain medication.
Market Dynamics
Industry Overview
The animal health industry is growing, driven by increased pet ownership and a greater focus on pet health and well-being. The market for osteoarthritis treatments for pets is substantial.
Positioning
PetVivo Holdings, Inc. is positioned as an innovator in the animal health space, offering a unique injectable treatment option for osteoarthritis in pets. Their primary competitive advantage is their patented hydrogel technology.
Total Addressable Market (TAM)
The TAM for osteoarthritis treatments in pets is estimated to be in the billions of dollars globally. PetVivo is positioned to capture a portion of this TAM with its Spryng product.
Upturn SWOT Analysis
Strengths
- Proprietary technology (OsteoCushion)
- Focus on a growing market (animal health)
- Injectable treatment option
Weaknesses
- Limited product portfolio
- Small market capitalization
- Reliance on single product for revenue
Opportunities
- Expanding product line
- Partnerships and collaborations
- Geographic expansion
Threats
- Competition from established animal health companies
- Regulatory hurdles
- Pricing pressures
Competitors and Market Share
Key Competitors
- VET
- ZTS
- MRK
Competitive Landscape
PetVivo's advantages lie in its unique technology, while its disadvantages include smaller size and limited resources compared to larger competitors like Zoetis, Merck and Virbac.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends are not available due to data limitations.
Future Projections: Future growth projections are not available due to data limitations.
Recent Initiatives: Recent initiatives include expanding sales and marketing efforts for Spryng, and continuing research and development on new product candidates.
Summary
PetVivo Holdings Inc. is a small animal health company focused on osteoarthritis treatment. Its proprietary technology is a potential strength, but it faces challenges due to its limited product line and strong competition. Expanding its product portfolio and securing partnerships are crucial for future growth, as is monitoring competition and regulatory changes.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings, Industry reports, Market analysis
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Market share values are estimates and may not reflect actual figures.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About PetVivo Holdings Inc
Exchange NASDAQ | Headquaters Edina, MN, United States | ||
IPO Launch date 2013-05-23 | CEO, President & Director Mr. John Lai | ||
Sector Healthcare | Industry Medical Devices | Full time employees 24 | Website https://www.petvivo.com |
Full time employees 24 | Website https://www.petvivo.com | ||
PetVivo Holdings, Inc., a biomedical device company, manufactures, commercializes, and licenses medical devices and therapeutics for animals in the United States. The company's lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. It also provides therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. is headquartered in Edina, Minnesota.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.